Fair Value Calculator Fair Value Calculator
EN DE

2609 (2609) Fair Value & Analysis

Healthcare · Market cap HK$4.8B

2 2609 2609 · HK
PriceHK$3.63
Fair ValueHK$0.6900
Upside-81.0%
Quality44/100
Watch 2609 for free — get notified when fair value or trend changes. Watch for free
Evidence: Medium Range HK$0.6600 – HK$0.7200

Fair value as of: Jul 2, 2026

From 14 valuation models · updated today

Share price −26.4% over the past month.

Price vs Fair Value (12 months)

HK$13.11 HK$2.74 Fair Value HK$0.6900 Jun 2025 Jul 2026

12‑month range HK$2.74 – HK$13.11 · fair‑value band HK$0.6600 – HK$0.7200 · the HK$3.63 price screens above the HK$0.6900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2609 (2609) currently trades at HK$3.63, while our model-based Fair Value estimate is HK$0.6900 — implying the stock looks roughly 81.0% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 2609 generated revenue of HK$1.1B at a net margin of -1.2%. Revenue declined 11.8% year over year. It earns a return on equity of -0.6%. Net debt stands at HK$63.0M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B
Revenue growth (YoY) -11.8%
Net margin -1.2%
Return on equity -0.6%
Free cash flow HK$184M FY2025
Operating margin 4.8%
More key figures
Net debt HK$63.0M FY2024

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2609 reported revenue of HK$1.1B in FY2025 versus HK$462M in FY2021, a compound +24.8%/yr. Reported net income was −HK$13.0M in FY2025.

Revenue +24.8%/yr
FY21 HK$462M
FY22 HK$803M
FY23 HK$1.1B
FY24 HK$1.2B
FY25 HK$1.1B
Net income
FY21 −HK$46.1M
FY22 −HK$58.0M
FY23 −HK$26.4M
FY24 −HK$13.5M
FY25 −HK$13.0M

Is 2609 fairly valued? → Check now

Similar stocks

6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc H1CA34 R$97.60 R$115.75 +19%
Fresenius SE FSNUY $11.27 $8.25 -27%
5225 5225 8.70 MYR 2.61 MYR -70%
IHHHF IHHHF $1.71 $1.26 -26%
Tenet Healthcare Corporation THC $178.75 $300.86 +68%
Rede D'Or São Luiz S.A RDOR3 R$33.83 R$46.94 +39%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 2609 (2609) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.6900 versus a price of HK$3.63 — about −81% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 2609?
Our model-based fair value for 2609 is HK$0.6900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$3.63.
What is the quality score of 2609?
2609 has a Quality Score of 44/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 2609 (2609)?
2609 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 2609?
The net profit margin of 2609 is about -1.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.